Genelux Stock Price, News & Analysis (NASDAQ:GNLX) $10.46 -0.41 (-3.77%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$10.28▼$11.1650-Day Range$10.38▼$28.7752-Week Range$5.35▼$40.98Volume115,415 shsAverage Volume127,583 shsMarket Capitalization$279.49 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Genelux MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside234.6% Upside$35.00 Price TargetShort InterestHealthy4.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 12 Articles This WeekInsider TradingSelling Shares$8.74 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.03) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector350th out of 949 stocksBiotechnology Industry4th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Genelux has a forecasted upside of 234.6% from its current price of $10.46.Amount of Analyst CoverageGenelux has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.07% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genelux has recently decreased by 8.85%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNLX. Previous Next 1.8 News and Social Media Coverage News SentimentGenelux has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Genelux this week, compared to 1 article on an average week.MarketBeat FollowsOnly 3 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,735,376.00 in company stock.Percentage Held by Insiders11.70% of the stock of Genelux is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.77% of the stock of Genelux is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genelux are expected to grow in the coming year, from ($1.03) to ($0.60) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Genelux Stock (NASDAQ:GNLX)Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.Read More GNLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNLX Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) Coverage Initiated by Analysts at HC WainwrightNovember 27, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Genelux (GNLX) with Buy RecommendationNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 27, 2023 | msn.comGenelux gets fast track status for Olvi-Vec in ovarian cancerNovember 27, 2023 | msn.comHC Wainwright starts Genelux at buy, cites Olvi-Vec potentialNovember 27, 2023 | markets.businessinsider.comGenelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian CancerNovember 27, 2023 | finance.yahoo.comGenelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian CancerNovember 25, 2023 | americanbankingnews.comGenelux (NASDAQ:GNLX) PT Lowered to $30.00November 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 23, 2023 | benzinga.comGenelux VP Sold $191K In Company StockNovember 18, 2023 | americanbankingnews.comBrookline Capital Management Equities Analysts Cut Earnings Estimates for Genelux Co. (NASDAQ:GNLX)November 17, 2023 | finance.yahoo.comGenelux Corporation (NASDAQ:GNLX) most popular amongst retail investors who own 57%, insiders hold 25%November 15, 2023 | msn.comGenelux GAAP EPS of -$0.20 misses by $0.02November 14, 2023 | finance.yahoo.comGenelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business UpdatesOctober 31, 2023 | morningstar.comGenelux Corp GNLXOctober 27, 2023 | msn.comGenelux 10% owner Aladar Szalay discloses sale of 5,704 sharesOctober 27, 2023 | benzinga.com10% Owner of Genelux Makes $110K SaleOctober 26, 2023 | msn.comGenelux Corporation 10% owner discloses sale of 49,987 sharesOctober 26, 2023 | benzinga.comGenelux Insider Trades Send a SignalOctober 26, 2023 | benzinga.comVP at Genelux Exercises Options Worth $97KOctober 11, 2023 | benzinga.comGenelux 10% Owner Trades Company's StockOctober 6, 2023 | msn.comGenelux (GNLX) Price Target Increased by 8.99% to 35.02October 5, 2023 | benzinga.comGenelux Recent Insider ActivitySeptember 28, 2023 | benzinga.comGenelux VP Acquires 5,200 Shares After Exercising Company Stock OptionsSeptember 28, 2023 | benzinga.comGenelux 10% Owner Sold $1.03M In Company StockSeptember 26, 2023 | benzinga.com10% Owner At This Health Care Company Sells $462K of StockSeptember 21, 2023 | benzinga.com10% Owner At This Health Care Company Sells $1.56M of StockSee More Headlines Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$40.00 Low Stock Price Target$30.00 Potential Upside/Downside+234.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,210,000.00 Net MarginsN/A Pretax Margin-10,514.71% Return on Equity-747.85% Return on Assets-115.08% Debt Debt-to-Equity RatioN/A Current Ratio3.56 Quick Ratio3.56 Sales & Book Value Annual Sales$11.07 million Price / Sales25.25 Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-6.93Miscellaneous Outstanding Shares26,720,000Free Float23,592,000Market Cap$279.49 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thomas Zindrick J.D. (Age 64)Chairman, CEO & President Comp: $500kMr. Sean Ryder J.D. (Age 54)General Counsel & Corporate Secretary Comp: $380kMs. Lourie S. Zak (Age 60)CFO & Principal Accounting Officer Dr. Joseph Cappello Ph.D. (Age 66)Chief Technical Officer Comp: $213.08kDr. Yong Yu Ph.D. (Age 52)Senior Vice President of Clinical Development Comp: $242.62kProf. Paul Scigalla M.D. (Age 77)Ph.D., Chief Medical Officer Mr. Ralph Smalling B.Sc. (Age 67)Head of Regulatory Affairs Ms. Caroline Jewett (Age 59)Head of Quality More ExecutivesKey CompetitorsFulcrum TherapeuticsNASDAQ:FULCMereo BioPharma GroupNASDAQ:MREONuvation BioNYSE:NUVBProcaps GroupNASDAQ:PROCKalVista PharmaceuticalsNASDAQ:KALVView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 7,026 shares on 11/24/2023Ownership: 0.026%Legal & General Group PlcBought 1,429 shares on 11/15/2023Ownership: 0.006%California State Teachers Retirement SystemBought 3,174 shares on 11/14/2023Ownership: 0.016%Northern Trust CorpBought 128,079 shares on 11/13/2023Ownership: 0.614%LPL Financial LLCBought 24,500 shares on 11/13/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions GNLX Stock Analysis - Frequently Asked Questions Should I buy or sell Genelux stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genelux in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GNLX shares. View GNLX analyst ratings or view top-rated stocks. What is Genelux's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price targets for Genelux's stock. Their GNLX share price targets range from $30.00 to $40.00. On average, they expect the company's stock price to reach $35.00 in the next year. This suggests a possible upside of 234.6% from the stock's current price. View analysts price targets for GNLX or view top-rated stocks among Wall Street analysts. How have GNLX shares performed in 2023? Genelux's stock was trading at $6.01 at the beginning of 2023. Since then, GNLX stock has increased by 74.0% and is now trading at $10.46. View the best growth stocks for 2023 here. Are investors shorting Genelux? Genelux saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 789,200 shares, a decrease of 8.8% from the October 31st total of 865,800 shares. Based on an average daily volume of 228,700 shares, the days-to-cover ratio is presently 3.5 days. Currently, 4.1% of the company's shares are short sold. View Genelux's Short Interest. When is Genelux's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our GNLX earnings forecast. When did Genelux IPO? (GNLX) raised $16 million in an IPO on Thursday, January 26th 2023. The company issued 2,500,000 shares at a price of $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Genelux's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Provident Wealth Management LLC (1.36%), AE Wealth Management LLC (0.79%), Northern Trust Corp (0.61%), Charles Schwab Investment Management Inc. (0.56%), Bank of New York Mellon Corp (0.22%) and AMG National Trust Bank (0.19%). Insiders that own company stock include Aladar Szalay, Caroline Jewett, Doug Samuelson, John Thomas, John W Smither, Joseph Cappello, Qian Zhang, Sean Ryder, Thomas Zindrick and Yong Yu. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GNLX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.